TYLIN

Indications

• Complicated skin and skin structure infections
• Complicated intra-abdominal infections
• Community-acquired pneumonia
• Non-gonococcal urethritis

Dosage

Children: Child 12–17 years: 500 mg IV every 12 hours for 7–14 days. Refer to the BNF for Children for specific dosing guidance.

Adults: Initial dose of 200 mg IV followed by 100 mg IV every 12 hours. Duration of treatment varies based on the infection but typically lasts 5 to 14 days.

Mechanism of action

Tigecycline exerts its antimicrobial effect by inhibiting protein synthesis in bacteria. It binds to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosomal acceptor site, thereby preventing the incorporation of amino acids into peptide chains. This action ultimately disrupts bacterial growth and reproduction.

Pharmacodynamics

Tigecycline demonstrates time-dependent bacteriostatic activity. Its effectiveness is influenced by the duration of exposure rather than peak concentration. The drug has a broad spectrum of activity against both aerobic and anaerobic bacteria, including resistant strains of Staphylococcus aureus and Enterococcus faecalis. It is important to note that tigecycline has no activity against Pseudomonas aeruginosa.

Pharmacokinetics

Tigecycline is administered intravenously and has a volume of distribution of approximately 7-10 L/kg, indicating extensive tissue distribution. It is partially metabolized in the liver and primarily excreted in feces, with a half-life of about 27 hours. Renal impairment does not significantly affect tigecycline clearance, but caution is advised in severe cases. The drug is not removed by dialysis.

Contra-indications

• Children under 12 years
• Diabetic foot infections

Adverse effects

• Decreased appetite
• Diarrhoea
• Dizziness
• Gastrointestinal discomfort
• Agranulocytosis
• Aplastic anaemia
• Nephritis
• Renal impairment
• Toxic epidermal necrolysis
• Hepatotoxicity

Interactions

• Carbamazepine (decreases exposure)
• Antifungals, azoles (increases exposure)
• Verapamil (increases exposure)
• Coumarins (affects anticoagulant effect)
• Ivacaftor (increases exposure)
• Lapatinib (increases exposure)
• Macrolides (increases exposure)
• Neratinib (increases exposure)
• Phenindione (increases anticoagulant effect)
• Ranolazine (increases exposure)

Precautions

• Caution in cholestasis
• Caution in hepatic impairment
• Caution in renal impairment

Pregnancy

Tetracyclines should not be given to pregnant women as they can affect skeletal development and may cause discoloration of the child's teeth.

Breast-feeding

Manufacturer advises avoiding use as tigecycline is present in milk in animal studies.

Storage

Store at room temperature, protect from light, and keep out of reach of children.

Formulations

• Tigecycline 50 mg powder for solution for infusion
• Tigecycline 50 mg tablet

Indications

• Solubilizing agent for poorly soluble drugs
• Excipient in pharmaceutical formulations
• Potential cholesterol-lowering agent
• Drug delivery systems

Dosage

Children: Refer to specific product guidelines for dosing information, as it varies based on formulation and application.

Adults: Refer to specific product guidelines for dosing information, as it varies based on formulation and application.

Mechanism of action

Betacyclodextrin acts by forming inclusion complexes with hydrophobic molecules. The hydrophobic portions of the guest molecules are encapsulated within the hydrophobic cavity of the cyclodextrin, while the hydrophilic outer surface of the cyclodextrin enhances the solubility of the complex in aqueous environments. This mechanism allows for improved drug solubility and stability, facilitating enhanced therapeutic effects.

Pharmacodynamics

The pharmacodynamic properties of betacyclodextrin are largely attributed to its ability to enhance the solubility and bioavailability of poorly soluble drugs. This leads to increased drug absorption and improved therapeutic outcomes. Additionally, betacyclodextrin may exert cholesterol-lowering effects by binding to bile acids and facilitating their excretion, thus reducing cholesterol reabsorption in the intestines.

Pharmacokinetics

Betacyclodextrin is not significantly absorbed from the gastrointestinal tract, which limits systemic exposure. However, its ability to form complexes with drugs can influence the pharmacokinetics of co-administered medications. The complexation can lead to altered absorption profiles, with potential impacts on the onset and duration of action of the drug. The elimination of betacyclodextrin is primarily through renal excretion, although the majority remains unabsorbed.

Pregnancy

There is limited information on the use of betacyclodextrin during pregnancy. Consult healthcare professionals for advice.

Breast-feeding

Limited data is available regarding the excretion of betacyclodextrin in human milk. Consult healthcare professionals for advice.

Storage

Store in a cool, dry place away from light.

Indications

• General anesthesia
• Induction of anesthesia
• Sedation in surgical procedures

Dosage

Children: Refer to the BNF for Children for specific dosing information based on age and weight.

Adults: Dosage varies depending on the procedure and patient characteristics; refer to specific clinical guidelines.

Mechanism of action

The exact mechanism of action of diethyl ether is not completely understood. It is believed to produce reversible loss of consciousness through interactions with membrane lipids and hydrophobic regions of membrane-bound proteins. The drug may alter the function of ion channel proteins, potentially affecting the GABA receptor, which is implicated in the modulation of neuronal excitability. Additionally, ether has been shown to increase plasma levels of adrenaline and noradrenaline, suggesting stimulation of neurosympathetic and adrenomedullary functions.

Pharmacodynamics

Ether induces general anesthesia characterized by a reversible loss of sensation and consciousness. Its anesthetic properties are thought to be the result of its effects on neuronal signaling and neurotransmitter systems, primarily by enhancing inhibitory neurotransmission through GABAergic pathways, leading to decreased neuronal excitability and a sedative effect.

Pharmacokinetics

Diethyl ether is rapidly absorbed through the lungs and is distributed widely in body tissues due to its lipophilicity. It is metabolized primarily in the liver, and elimination occurs through exhalation and minor metabolic pathways. The onset of action is swift, with effects seen within minutes of inhalation, and recovery is equally rapid upon cessation of exposure.

Adverse effects

• Nausea
• Vomiting
• Respiratory depression
• Cardiovascular instability
• Hypotension
• Delayed recovery from anesthesia

Interactions

• May potentiate the effects of other central nervous system depressants
• Increased risk of respiratory depression when used with opioids
• Potential interaction with alcohol, leading to enhanced sedation

Precautions

• Use with caution in patients with respiratory or cardiovascular diseases
• Monitor for signs of respiratory depression
• Ensure appropriate equipment and personnel are available for anesthesia

Pregnancy

Use is contraindicated during pregnancy due to potential risks to the fetus.

Breast-feeding

Use with caution; limited data available on excretion in breast milk.

Storage

Store in a cool, dry place, away from heat and direct sunlight. Keep tightly closed.

Formulations

• Inhalation solution
• Liquid for inhalation

Indications

• Adjustment of pH in pharmaceutical formulations
• Facilitation of drug absorption
• Used in sterile preparations

Dosage

Children: Refer to specific product guidelines for dosing information, as hydrochloric acid is typically used in a controlled setting based on formulation requirements.

Adults: Refer to specific product guidelines for dosing information, as hydrochloric acid is typically used in a controlled setting based on formulation requirements.

Mechanism of action

Hydrochloric acid dissociates in aqueous solution to release hydrogen ions (H+), leading to a decrease in pH. This acidic environment promotes the activation of pepsinogen to pepsin, an enzyme essential for protein digestion. Additionally, the acidity aids in the absorption of certain minerals and drugs that require an acidic environment for optimal bioavailability.

Pharmacodynamics

The primary pharmacodynamic action of hydrochloric acid is the maintenance of gastric acidity, which is essential for normal digestive processes. The acidic environment helps in denaturing proteins, activating digestive enzymes, and providing a barrier against pathogenic microorganisms. Its effects can influence the absorption and efficacy of various medications, particularly those that are pH-dependent.

Pharmacokinetics

Hydrochloric acid does not undergo significant systemic absorption when used in its normal contexts, as it acts locally within the gastrointestinal tract. The amount of hydrochloric acid produced by the stomach varies with food intake and physiological needs. It is secreted by parietal cells in the gastric mucosa, and its secretion is regulated by neural, hormonal, and local factors. The half-life of hydrochloric acid is not applicable as it is continuously produced and neutralized within the gastrointestinal tract.

Contra-indications

• Hypersensitivity to hydrochloric acid or any of its components
• Severe renal impairment
• Active gastrointestinal bleeding

Adverse effects

• Abdominal pain
• Diarrhea
• Nausea
• Vomiting
• Esophageal irritation
• Gastric mucosal irritation
• Electrolyte imbalances

Interactions

• May interact with alkaline substances, potentially neutralizing hydrochloric acid
• Caution with antacids as they may affect the efficacy of hydrochloric acid

Precautions

• Use with caution in patients with a history of gastritis or gastric ulcers
• Monitor electrolytes in prolonged use
• Use cautiously in patients with respiratory conditions due to potential aspiration risks

Pregnancy

Hydrochloric acid is classified as a category C drug. Use during pregnancy only if clearly needed and the potential benefits justify the risks to the fetus.

Breast-feeding

There is limited data on the excretion of hydrochloric acid in human milk. Use with caution during breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight and heat. Ensure the container is tightly closed.

Formulations

• Oral solutions
• Injectable forms
• Tablets

Indications

• Pain management
• Vaccination
• Antibiotic therapy
• Hormonal therapies
• Anesthesia
• Nutritional support
• Chemotherapy

Dosage

Children: Refer to specific drug guidelines for paediatric dosing, as it requires careful consideration of weight and age.

Adults: Refer to specific drug guidelines for adult dosing, as it varies widely depending on the medication and clinical condition.

Mechanism of action

The mechanism of action of injected drugs varies widely based on the specific medication being administered. Generally, injected drugs enter the bloodstream directly, allowing them to circulate rapidly throughout the body. For instance, antibiotics may work by inhibiting bacterial cell wall synthesis, while analgesics may modulate pain pathways in the central nervous system. Each drug has unique pathways through which it achieves its therapeutic effects.

Pharmacodynamics

Pharmacodynamics refers to the effects of drugs on the body and their mechanisms of action. For injectable medications, effects can be immediate or delayed, depending on the drug's formulation and route of administration. Factors influencing pharmacodynamics include receptor affinity, drug concentration, and the presence of other substances that may enhance or inhibit the drug's effects. For example, some injectable drugs may require specific receptors to exert their effects, while others may have a broader range of action.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of injected drugs. After administration, drugs are rapidly absorbed into the bloodstream, leading to quick therapeutic effects. The distribution depends on factors such as blood flow, tissue permeability, and protein binding. Drugs are metabolized primarily in the liver and excreted through the kidneys or bile. The pharmacokinetic profile can vary widely based on the drug's chemical nature, dosage, and individual patient factors.

Pregnancy

Safety during pregnancy depends on the specific injection and its active ingredients. It is essential to consult a healthcare professional for guidance.

Breast-feeding

The safety of injections during breastfeeding varies by the specific medication. It is recommended to seek advice from a healthcare provider.

Storage

Store injections as per manufacturer's guidelines, usually in a cool, dry place away from direct sunlight. Some may require refrigeration.

Indications

• Attention Deficit Hyperactivity Disorder (ADHD)
• Narcolepsy
• Chronic fatigue syndrome
• Depression (off-label)

Dosage

Children: Refer to the BNF for Children for appropriate dosing information in paediatric patients.

Adults: Refer to clinical guidelines or prescribing information for specific dosing recommendations, as they vary based on indication and individual patient factors.

Mechanism of action

Make primarily acts as a monoamine reuptake inhibitor, increasing the levels of neurotransmitters such as dopamine, norepinephrine, and serotonin in the synaptic cleft. This action is thought to contribute to its stimulant effects, enhancing mood and alertness.

Pharmacodynamics

The pharmacodynamics of Make involve the modulation of neurotransmitter systems in the brain. By inhibiting the reuptake of monoamines, it enhances synaptic transmission and increases overall neuronal excitability. It may also exhibit effects on peripheral adrenergic receptors, leading to increased heart rate and blood pressure.

Pharmacokinetics

Make is absorbed rapidly after administration, with peak plasma concentrations occurring within 1-2 hours. It is extensively metabolized in the liver, primarily via cytochrome P450 enzymes, and has a half-life of approximately 6-8 hours. Elimination occurs mainly through renal excretion of metabolites.

Pregnancy

The safety of make during pregnancy has not been established. Caution should be exercised.

Breast-feeding

It is unknown whether make is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and light. Keep out of reach of children.

Dosage

Children: Refer to the specific drug's dosing guidelines for children.

Adults: Refer to the specific drug's dosing guidelines for adults.

Pregnancy

Consult with a healthcare provider, as safety data may vary depending on the specific drug and its classification.

Breast-feeding

Consult with a healthcare provider, as safety data may vary depending on the specific drug and its classification.

Storage

Store in a cool, dry place away from direct sunlight and moisture. Keep out of reach of children.

Dosage

Children: Refer to specific drug guidelines in the BNF for Children for appropriate dosing information.

Adults: Refer to specific drug guidelines in the BNF for appropriate dosing information.

Mechanism of action

The mechanism of action will vary significantly depending on the specific drug referred to as 'sufficient.' Generally, mechanisms of action may include receptor agonism or antagonism, enzyme inhibition, or modulation of signaling pathways within cells. Understanding the specific drug's pharmacodynamics is crucial for determining its therapeutic efficacy.

Pharmacodynamics

Pharmacodynamics involves the study of the biochemical and physiological effects of drugs and their mechanisms of action. It encompasses the interactions between drug molecules and target receptors, the resulting cellular responses, and the overall therapeutic effects observed in patients. The relationship between drug concentration and effect is fundamental to understanding drug efficacy and safety.

Pharmacokinetics

Pharmacokinetics describes how a drug is absorbed, distributed, metabolized, and excreted in the body. Key parameters include bioavailability, volume of distribution, clearance, and half-life. These factors influence dosing regimens and the timing of therapeutic effects. Individual patient characteristics, such as age, sex, organ function, and genetic factors, can also impact pharmacokinetic profiles.

Pregnancy

Consult with a healthcare provider before use. Insufficient data on safety.

Breast-feeding

Consult with a healthcare provider before use. Insufficient data on safety.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Constipation
• Bowel preparation for surgical procedures
• Management of fecal impaction

Dosage

Children: Refer to established guidelines for paediatric dosing based on age, weight, and clinical condition.

Adults: Refer to established guidelines for specific dosing based on clinical condition and formulation used.

Mechanism of action

Sulphobutyl functions as an osmotic laxative. It draws water into the intestinal lumen through osmosis, which softens the stool and promotes peristalsis, facilitating bowel evacuation. This action is primarily mediated through its sulfate group, which enhances its solubility in gastrointestinal fluids.

Pharmacodynamics

The pharmacodynamic effects of sulphobutyl are characterized by its ability to increase the frequency of bowel movements and reduce the consistency of stool. Its osmotic properties lead to an increased intraluminal pressure, which stimulates intestinal motility. The onset of action can vary, depending on the formulation and individual patient factors.

Pharmacokinetics

Sulphobutyl is not absorbed significantly from the gastrointestinal tract; its effects are localized primarily in the intestines. The compound is eliminated unchanged in the feces. The pharmacokinetic profile indicates a rapid onset of action, usually within a few hours after ingestion, with the duration of effect lasting several hours. Variability in absorption and metabolism may occur based on individual patient characteristics.

Pregnancy

There are no adequate and well-controlled studies in pregnant women. Sulphobutyl should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether sulphobutyl is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Indications

• Obesity
• Overweight with weight-related comorbidities
• Weight management in patients with metabolic syndrome
• Prevention of weight regain after weight loss

Dosage

Children: Refer to the BNF for Children for appropriate dosing information in paediatric populations.

Adults: Refer to specific product information or clinical guidelines for recommended dosing. Doses may vary based on the specific medication and patient factors.

Mechanism of action

Weight management medications may work through various mechanisms, including appetite suppression, increasing metabolic rate, or altering the absorption of nutrients. For instance, some drugs may act on neurotransmitters in the brain that regulate hunger and satiety, while others may enhance energy expenditure or inhibit fat storage.

Pharmacodynamics

The pharmacodynamic effects of weight management drugs vary by class. Appetite suppressants typically increase feelings of fullness or reduce hunger, leading to decreased caloric intake. Medications that alter metabolism may increase the rate at which the body burns calories or fat. Overall, the goal is to create a caloric deficit that promotes weight loss.

Pharmacokinetics

Pharmacokinetics of weight management medications can differ significantly based on the specific drug. Factors such as absorption, distribution, metabolism, and excretion can influence the onset and duration of action. Many weight loss medications are absorbed through the gastrointestinal tract, metabolized in the liver, and excreted via the kidneys. The half-life of these drugs can vary, affecting dosing frequency and patient compliance.

Pregnancy

Weight management should be approached cautiously during pregnancy, with a focus on balanced nutrition and gradual weight loss only if clinically indicated.

Breast-feeding

Weight loss medications are generally not recommended during breastfeeding; consult a healthcare provider for specific guidance.

Storage

Store in a cool, dry place, away from direct sunlight and out of reach of children.

Mechanism of action

The mechanism of action by which .... ethyl ether produce/s/ reversible loss of consciousness is still unclear. Anesthesia can be produced by a wide variety of chemical agents, ranging from inert rare gases to steriodal molecules. This apparent lack of specificity, together with the observation that general anesthesia can be reversed by high pressure, poses a unique pharmacological problem. Most theories concern interaction of anesthetics with either membrane lipids or hydrophobic regions of specificic membrane-bound proteins. One hypothesis is that the anesthetic changes the function of an ion channel protein by modifying the conformation of the protein. Some investigators suggest that the GABA receptor may be the ion channel protein that is affected by inhalation of anesthetic agents... The most appropriate concept for the mechanism of general anesthesia /may be/ a the heterogenous site of anesthetic action, including both lipid and protein membrane components linked with neuronal function. In chronically catheterized rats, diethyl ether increased plasma adrenaline and noradrenaline concentrations indicating that this drug stimulates both neurosympathetic and adrenomedullary functions. These effects appear to be centrally mediated, since ganglionic blockade or spinal transection completely counteracted the diethyl ether induced increases in plasma calcium levels. Hippocampal EEG signals derived from chronically implanted electrodes in the freely moving rat were recorded before and after administration of centrally acting drugs, and analyzed by power and coherence spectra. Diethyl ether induced a low frequency (3-6 c/s) theta power and coherence peak in the immobile rat, which was sensitive to atropine or scopolamine. The residue spectrum, defined as the EEG spectrum with the theta harmonics removed, was sensitive to centrally acting drugs. Diethyl ether suppressed fast waves of 50-100 c/s, and some conditions, enhanced 15-50 c/s waves. The plasma beta-endorphin responses to ether and handling stress were examined in animals of various ages. At each age studied there was a significant, stress-induced elevation of plasma beta-endorphin-like immunoreactivity levels were higher in animals 3,7, and 14 days of age than in adults. Cortical action potential activity is suppressed by ether anesthesia and is not affected when sensory fibers in the sciatic nerve are stimulated. Consequently, ether blocks sensory pathways to the cortex; the blockade occurs even before cortical activity is entirely suspended. In contrast, pentobarbital suppresses activity in the cortex without blocking the sensory path to it during sciatic nerve stimulation.